Login to Your Account



Clinic Roundup


Wednesday, September 19, 2012
• GeNeuro SA, of Geneva, launched a Phase IIa study with GNbAC1 , its humanized monoclonal antibody targeting a human endogenous retrovirus, in multiple sclerosis (MS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription